Member Info for MisterPositive

GENinCode PLC, a UK-based company specializing in cardiovascular disease (CVD) genetic testing, estimates its Total Addressable Market (TAM) at $10.5 billion.

GEN inCode

+3

Their focused Serviceable Available Market (SAM) is estimated at $4.5 billion.

GEN inCode

Key Market Data (as of mid-2025/early 2026)

Targeted Patient Pool: Initial market scoping indicates an addressable population of 21 million patients.

Key Prescription Potential: Approximately 8.5 million patients are expected to be prescribed the CARDIO inCode-Score test once comprehensive insurance coverage is secured.

Global Context: The broader global cardiogenomics market is projected to reach $3.57 billion by 2030.

Primary Growth Areas: The US, UK, and Europe, driven by increasing focus on preventative CVD care.

GEN inCode

+2

Product Portfolio Drivers

CARDIO inCode-Score: A polygenic risk score test for coronary heart disease, which recently secured New York State approval and is seeking FDA approval.

LiPID inCode: A diagnostic test for familial hypercholesterolemia (FH) used within the NHS.

ROCA Test: Risk assessment for ovarian cancer.

ADVFN UK

+1

As of early 2026, the company is focusing on commercial expansion in the US, Italy, and Germany to capture this market, with over 20 top-tier institutional sites already onboarded.

Looking good here with early signs of an attempt to break out higher.

Upside here is MASSIVE without any doubt. NPV numbers speak for themselves.

Potential to 10 bag and higher is very clear.

Looking good here with early signs of an attempt to break out higher out of the current price range.

Upside here is MASSIVE without any doubt.

Potential to 10-20 bag and higher is very clear.

Looking good here with early signs of an attempt to break out higher out of the current price range.

Upside here is MASSIVE without any doubt.

Potential to 10-20 bag and higher is very clear.

Yes. Looks like warrants are still churning through. It's quite frustrating but has to be dealt with.

IMM went from 1.40 to 19.40 in 2025.

Can GENI mirror similar run in 2026 ?

With target market of +$10.5 Billion and New York State approval already received at $500 per test, this could do even better than what IMM did last year in my opinion.

Explosive UPSIDE ahead.

RNS next week !!

Should trigger huge Upward price move.

Manufacturing & Distribution deal all ready to go with NASDAQ listed ThermoFisher 🙂

CDL is very strong candidate for £50m MCap given the high grade Gold deposits it is sitting on.

Drill action to start very soon.

Current MCap is way too low in my view.

Successful drill results and this could be over +3p

Average Price Target: 7.50p

High Estimate: 11.50p

Consensus Rating: Strong Buy

Based on analyst coverage as of early 2026, Genincode PLC (GENI) has a consensus Strong Buy rating with a 12-month average price target of 7.50p to 8.00p. This represents a significant potential upside, often cited over 500% from recent trading prices.

Tapender.

Yes all Hi tech US companies including US Aerospace giants like GE. Raytheon, etc are in a pickle to source Rare Earths to deliver on their Multi-billion orders.

Only got few months before Jan 2027 before US ban kicks in.

Monte Muambe aiming for 2027 production.

USTDA grant should fast track production.

Very strong possibility we will break +5p today.

MRE on Tuesday and this will open at 6p

Https://finance.yahoo.com/markets/stocks/articles/ge-aerospace-faces-rare-earth-150526755.html

GE Aerospace Faces Rare Earth Reset As U.S. Rules Tighten https://share.google/tJK0L8WlE0XHlT0er

There are 2.5m warrants @ 5p which is very small but could also get flushed through around 7p - 8p price range enroute to 10p

5p+ or higher would be great level going into next week.

Henry

What upward revision you expecting from Zeus?

20p may be?

After the MRE next week. I would expect other Brokers/Analysts also to initiate coverage with additional price targets.

And once Heavy rare earths are brought into the frame, then we should be looking at 30p+

Just my thoughts....suggestions are welcome.

Zeus Capital must be busy working on Upward revision to their old 8.9p valuation.

That is out of date now.

Some Buys at 4.64 showing as Sells.

Think MMs are low on stock.

4.78

5p should be here soon.